This article is
- freely available
Harnessing Dendritic Cells for Tumor Antigen Presentation
Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen 6525 GA, The Netherlands
Division of Molecular Immunology, Cincinnati Children’s Hospital Research Foundation, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
* Author to whom correspondence should be addressed.
Received: 14 March 2011; in revised form: 14 April 2011 / Accepted: 19 April 2011 / Published: 26 April 2011
Abstract: Dendritic cells (DC) are professional antigen presenting cells that are crucial for the induction of anti-tumor T cell responses. As a consequence, research has focused on the harnessing of DCs for therapeutic interventions. Although current strategies employing ex vivo-generated and tumor-antigen loaded DCs have been proven feasible, there are still many obstacles to overcome in order to improve clinical trial successes and offset the cost and complexity of customized cell therapy. This review focuses on one of these obstacles and a pivotal step for the priming of tumor-specific CD8+ and CD4+ T cells; the in vitro loading of DCs with tumor antigens.
Keywords: dendritic cell; tumor antigen; antigen presentation; antigen processing
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Nierkens, S.; Janssen, E.M. Harnessing Dendritic Cells for Tumor Antigen Presentation. Cancers 2011, 3, 2195-2213.
Nierkens S, Janssen EM. Harnessing Dendritic Cells for Tumor Antigen Presentation. Cancers. 2011; 3(2):2195-2213.
Nierkens, Stefan; Janssen, Edith M. 2011. "Harnessing Dendritic Cells for Tumor Antigen Presentation." Cancers 3, no. 2: 2195-2213.